Relevant bibliographies by topics / Antibody

Academic literature on the topic 'Antibody'

Author: Grafiati
Published: 4 June 2021
Last updated: 7 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antibody.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antibody"

1

Panda, Manasi. "Rabies-Monoclonal Antibody - A Perspective." Journal of Communicable Diseases 54, no. 03 (September 30, 2022): 22–26. http://dx.doi.org/10.24321/0019.5138.202285.

Full text
Abstract:
Rabies is an acute viral zoonotic disease that affects the central nervous system (CNS) of all warm-blooded animals, including mammals. Research studies and experience from across the world have demonstrated that appropriate administration of a combination of (a) local wound treatment, (b) anti-rabies vaccination and (c) passive immunization have proved to be quite effective in preventing the occurrence of rabies. As far as passive immunization is concerned, polyclonal plasma-derived rabies immunoglobulins (RIG) pose a number of limitations with scarce supply, high cost, etc. amongst many others. On the contrary Rabies Monoclonal Antibodies (R-mAb) are much cheaper, permit longer-term storage, etc. and hence could offer a more standardized, accessible, affordable and equally efficacious and safer alternative to RIG. Accordingly, this article has tried to throw light on the transition from RIG to monoclonal antibody-based Post Exposure Prophylaxis (PEP) which has been recommended by the WHO strongly. The advantages, limitations and future scope of R-mAb have been discussed at length to give a comprehensive idea about this novel invention in the field of medicine.
APA, Harvard, Vancouver, ISO, and other styles
2

B, Aswin, Sumanth T, and Ravi Madhusudhana. "Pregnancy and Antiphospholipid Antibody Syndrome." Indian Journal of Anesthesia and Analgesia 9, no. 3 (June 15, 2022): 41–43. http://dx.doi.org/10.21088/ijaa.2349.8471.9322.14.

Full text
Abstract:
Introduction: ALPA is an autoimmune hypercoagulable state caused by antiphospholipid antibodies. It is characterized by thrombotic episodes in arteries, veins and pregnancy related complications like still birth, preterm delivery, miscarriage and severe preeclampsia. We report a case of APLA syndrome due to its rarity. Case Report: A 28 year old woman with a history of two previous abortions and positive serology for APLAs with 9 months gestation came to our hospital for safe confinement. She was diagnosed as primary APLA syndrome in view of bad obstetric history and positive lupus anticoagulant. She is a known hypothyroidism. She was on Injection Enoxaparin 0.6 ml OD for 1 year which was changed to unfractionated heparin 14000 units OD subcutaneously after admitting to our hospital. In view of bad obstetric history, an elective caesarean section was planned. Unfractionated heparin was stopped 24 hours before surgery. Preoperative investigations revealed a normal APTT, PT, INR. Spinal anesthesia given in L3–L4 inter-spinal space with 25G needle after preloading with 500 ml crystalloids and a sensory block up to T6 was attained. She delivered a single live male child with APGAR score 9. Injection Oxytocin 15 units was given intraoperatively. The further perioperative course was uneventful. She was restarted on Injection Enoxaparin 0.6ml OD for 6 weeks.
APA, Harvard, Vancouver, ISO, and other styles
3

Ta, Angeline N., and Brian R. McNaughton. "Antibody and antibody mimetic immunotherapeutics." Future Medicinal Chemistry 9, no. 12 (August 2017): 1301–4. http://dx.doi.org/10.4155/fmc-2017-0057.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tan, Lee K., and Sherie L. Morrison. "Antibody structure and antibody engineering." Advanced Drug Delivery Reviews 2, no. 2 (November 1988): 129–42. http://dx.doi.org/10.1016/0169-409x(88)90030-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kabat, EA. "Antibody complementarity and antibody structure." Journal of Immunology 141, no. 7 (October 1, 1988): 25–36. http://dx.doi.org/10.4049/jimmunol.141.7.25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lockshin, Michael D. "Antiphospholipid antibody and antiphospholipid antibody syndrome." Current Opinion in Rheumatology 3, no. 5 (October 1991): 797–802. http://dx.doi.org/10.1097/00002281-199110000-00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Aryastami, Ni Ketut, Prisca Petty Arfines, Vivi Setiawaty, and Siti Isfandari. "Factors associated with measles antibody titers in children aged 12-36 months in Indonesia: an analysis of National Health Research 2013." Health Science Journal of Indonesia 12, no. 2 (December 16, 2021): 97–103. http://dx.doi.org/10.22435/hsji.v12i2.5356.

Full text
Abstract:
Background: The immunization program in Indonesia has been implemented since 1956 started to eradicate smallpox and expanded until 1980, including Measles. The timely and complete implementation of basic immunization is the main strategy to protect the population, including outbreak prevention. The purpose of this study is to determine the level immunity of Measles antibody as the outcome of completed basic immunization and its contributors in children aged 12-36 months. Methods: This study is a secondary data analysis of the Indonesia Basic Health Survey (RISKESDAS) 2013. The analysis was carried out on a serological sample of the antibody titer of children aged 12-36 months, totaling 229 samples. The sample inclusion criteria were children who had complete sociodemographics data, basic immunization records and Measles antibody titer data. Measles examination was carried out using the Enzyme-Linked Immunosorbent Assay (ELISA) method. Results: Incomplete immunization, being a boy, and lack of cleanliness in the family room were significantly associated with lower measles antibody levels in children. Having each variable controlled, completeness of immunization (OR=1,99; p=0.018; 95% CI=1.124-3.544) and gender of boy (OR=2.0; p=0.016; 95% CI=1.137-3.515) remain as significant variables for antibody’s titer. Conclusion: The completeness of immunization has a significant association towards titer antibody of Measles in children. Immunization completeness is an actual effort to reach herd immunity in children and to prevent measles outbreak in the community. Adequate health promotion is needed to change people's behavior to believe in the safety and importance of implementing complete basic immunization for children even in pandemic conditions. Keywords: antibody titer, immunization, children aged 12-36 months, Indonesia, measles Abstrak Latar belakang: Program imunisasi di Indonesia telah dilaksanakan sejak tahun 1956 yang dimulai dengan pemberantasan cacar yang diperluas hingga tahun 1980, termasuk campak. Pelaksanaan imunisasi dasar yang tepat waktu dan lengkap merupakan strategi utama untuk perlindungan penduduk, termasuk pencegahan Kejadian Luar Biasa (KLB). Tujuan dari penelitian ini untuk mengetahui tingkatan kekebalan antibodi Campak sebagai hasil dari kelengkapan imunisasi dasar dan faktor yang berkontribusi pada anak usia 12-36 bulan. Metode: Penelitian ini merupakan analisis data sekunder Riset Kesehatan Dasar Indonesia (RISKESDAS) 2013. Analisis dilakukan pada sampel serologi titer antibodi anak usia 12-36 bulan yang berjumlah 229 sampel. Kriteria inklusi sampel adalah anak yang memiliki data sosiodemografi lengkap, catatan imunisasi dasar dan data titer antibodi Campak. Pemeriksaan campak dilakukan dengan metode Enzyme-Linked Immunosorbent Assay (ELISA). Hasil: Imunisasi yang tidak lengkap, berjenis kelamin laki-laki, dan kurangnya kebersihan di ruang keluarga berhubungan bermakna dengan rendahnya tingkat antibodi campak pada anak. Setelah masing-masing variabel terkontrol, kelengkapan imunisasi (OR=1,99; p=0,018; 95% CI=1.124-3.544) dan jenis kelamin laki-laki (OR=2.0; p=0.016; 95% CI=1.137-3.515) merupakan variabel yang tetap berhubungan dengan titer antibodi secara signifikan. Kesimpulan: Kelengkapan imunisasi memiliki hubungan yang bermakna terhadap titer antibodi Campak pada anak. Kelengkapan imunisasi merupakan upaya nyata untuk mencapai herd immunity pada anak dan mencegah wabah campak di masyarakat. Promosi kesehatan yang memadai diperlukan untuk mengubah perilaku masyarakat agar percaya akan keamanan dan pentingnya pelaksanaan imunisasi dasar lengkap bagi anak meskipun dalam kondisi pandemi. Kata kunci: titer antibodi, imunisasi, anak usia 12-36 bulan, Indonesia, campak
APA, Harvard, Vancouver, ISO, and other styles
8

Rotty, Ivonne, Erwin G. Kristanto, Sekplin Sekeon, Neni Ekawardani, and Henny R. Liwe. "Formation of SARS-CoV-2 Specific Antibody after vaccination." e-CliniC 10, no. 1 (January 18, 2022): 16. http://dx.doi.org/10.35790/ecl.v10i1.37193.

Full text
Abstract:
Abstract: Vaccination is considered as the most effective solution for the SARS-COV-2 pandemic problem. Therefore, an understanding of the effectiveness of vaccination is now very important, both to design a better response to SARS-CoV-2, as well as to provide education for prospective vaccination participants. This study was aimed to obtain the description of specific antibody in SARS-CoV2 vaccinated individuals. This was a cohort-design study. SARS-CoV-2 specific antibody was measured wiht the Electro Chemiluminescence Immunoassay (ECLIA) method. This study was carried out at Prof. Dr. R. D. Kandou Hospital with 28 subjects; all were examined three times with an interval of three weeks. The first antibody examination revealed antibody formation (IgG) with a range of 3.6-1825 AU/mL with a median of 418.3 AU/mL and a mean of 525.6 AU/mL. In the second and third examinations, the median antibody titer value in the elderly group was recorded at 482.9 AU/mL and 631.3 AU/mL respectively, which were higher than the group of non-elderly subjects who were recorded to have a median of 391.9 AU/mL in the second examination and 401.6 AU/mL in the third examination. In conclusion, vaccination causes specific immunity, and the effectiveness of vaccination for the formation of specific antibodies (IgG) in the elderly group is good, although it takes a longer time compared to the non-elderly group. Moreover, the antibody formed after 63 days from the first vaccination in the elderly group is higher than in the non-elderly group.Keywords: SARS-COV-2; antibody; vaccination Abstrak: Penanggulangan pandemi SARS-COV-2 yang dianggap paling efektif hingga saat ini ialah vaksinasi, yang dilengkapi dengan penerapan protokol kesehatan. Pemahaman tentang efektivitas vaksinasi saat ini menjadi amat penting, baik untuk merancang penanggulangan SARS-CoV-2 yang lebih baik, maupun untuk memberikan edukasi bagi calon peserta vaksinasi. Penelitian ini bertujuan untuk mendapatkan gambaran antibodi spesifik yang terbentuk pada penerima vaksinasi SARS-CoV2 menggunakan desain cohort. Pengukuran antibodi spesifik SARS-CoV-2 menggunakan metode Electro Chemiluminescence Immunoassay (ECLIA). Penelitian dilaksanakan di RSUP Prof. Dr. R. D Kandou dengan jumlah subjek 28 orang, masing-masing diperiksa tiga kali dengan jeda waktu tiga minggu. Pada pemeriksaan antibodi pertama ditemukan pembentukan antibodi (IgG) dengan range 3,6-1825 AU/mL dengan median 418,3 AU/mL dan rerata 525,6 AU/mL. Pada pemeriksaan kedua dan ketiga, nilai median titer antibodi pada kelompok lanjut usia, berturut-turut tercatat 482,9 AU/mL dan 631,3 AU/mL pada pemeriksaan ketiga, lebih tinggi dibanding dibanding kelompok subjek non lansia yang tercatat memiliki median 391,9 AU/mL pada pemeriksaan kedua dan 401,6 AU/mL pada pemeriksaan ketiga. Simpulan penelitian ini ialah vaksinasi menimbulkan imunitas spesifik, dan efektivitas vaksinasi untuk pembentukan antibodi spesifik (IgG) pada kelompok lanjut usia baik, walau membutuhkan waktu yang lebih panjang dibanding kelompok non lanjut usia. Antibodi yang terbentuk pasca vaksinasi 63 hari setelah pemberian vaksinasi pertama pada kelompok lanjut usia lebih tinggi dibanding kelompok non usia lanjut.Kata kunci: SARS-CoV-2; antibodi; vaksinasi
APA, Harvard, Vancouver, ISO, and other styles
9

Nur Hasanah, Aliya. "Molekular Imprinting Polimer Sebagai "Antibody Mimic" dalam Pengujian Klinik." Farmasetika.com (Online) 1, no. 2 (October 3, 2016): 4. http://dx.doi.org/10.24198/farmasetika.v1i2.9705.

Full text
Abstract:
45 tahun lalu merupakan pertama kali imprinting diperkenalkan dalam dunia polimer organik oleh Gunter Wulff’s. Molekular imprinting polimer adalah material yang disiapkan dengan keberadaan suatu molekul sebagai cetakan untuk pembentukan sisi ikatan komplementer dengan molekul cetakan. Molekular imprinting polimer dapat menjadi model buatan untuk sisi ikatan biologi yang umumnya ditemukan pada reseptor dan antibodi. Molekular imprinting polimer juga dapat digunakan untuk sistem deteksi yang mengikuti alur sisi ikatan biologi. Molekular imprinting polimer memiliki karakter yang lebih baik dibanding antibodi dalam hal stabilitas fisikokimia, mekanik dan ketahanan terhadap panas. Tetapi, dibalik banyaknya keuntungan yang ditawarkan oleh molekular imprinting polimer sebagai “plastic antibody” atau “antibody mimic”, masih banyak hal yang harus diperbaiki agar material ini dapat betul-betul menggantikan antibodi sehingga bisa digunakan secara luas dalam immunoassay.
APA, Harvard, Vancouver, ISO, and other styles
10

Karaveli, Guner, Ebru Gok Oguz, Tolga Yildirim, Zafer Ercan, Ozgur Merhametsiz, Ayhan Haspulat, and Deniz Ayli. "Plasmapheresis in Chronic Active Antibody-Mediated Rejection." Turkish Nephrology Dialysis Transplantation 24, no. 01 (January 26, 2015): 123–25. http://dx.doi.org/10.5262/tndt.2015.1001.20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Antibody"

1

Krawczyk, Konrad. "Computational antibody design." Thesis, University of Oxford, 2013. https://ora.ox.ac.uk/objects/uuid:530a7e81-8525-4cb6-a54f-76827b565ff9.

Full text
Abstract:
Antibodies are a class of proteins vital in mediating immune responses in vertebrates. Their binding site is highly malleable, allowing them to bind virtually any antigen. The versatility of antibody binding sites has received much attention from the pharmaceutical industry, marking them out as the most important category of biopharmaceuticals. The development of antibodies which bind to a specific antigen has thus far been achieved by costly and time-consuming experimental screening campaigns. However, in recent years computational approaches to antibody design have started to emerge, which offer an alternative. Computational antibody design techniques focus on determination of the binding site on the antibody, antibody-modelling, antibody-antigen docking and prediction of the binding site on the antigen. Here, we explore aspects of computational antibody design with the aim of gaining a better understanding of antibody-antigen interactions and improving existing artificial antibody design tools. We start by demonstrating our structural antibody database which has become a primary resource for antibody structural information. This is followed by a detailed analysis of the antibodyantigen interactions. The information gathered from this analysis allowed us to create an antibody contact site prediction tool, Antibody i-Patch. This tool was then employed to develop a local antibody-antigen docking pipeline, which used knowledge of the binding site of the antigen. We then tackled the global antibody-antigen docking problem by developing EpiPred, antigen binding site predictor which was employed in our global antibody-antigen docking pipeline.
APA, Harvard, Vancouver, ISO, and other styles
2

Ohlin, Mats. "Human monoclonal antibody technology a tool to investigate human antibody repertoires /." Lund : Dept. of Immunotechnology, Lund University, 1992. http://catalog.hathitrust.org/api/volumes/oclc/39693827.html.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rostedt, Punga Anna. "MuSK Antibody(+) Versus AChR Antibody(+) Myasthenia Gravis : Clinical, Neurophysiological and Morphological Aspects." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl [distributör], 2007. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-7408.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Harasym, Troy O. "Antibody-targeted liposomal systems." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/nq25066.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Low, Nigel Murray. "Mimicking antibody affinity maturation." Thesis, University of Cambridge, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.364567.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Marks, Cara. "Antibody structure and function." Thesis, University of Cambridge, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.260558.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Nowak, Jaroslaw. "Understanding antibody binding sites." Thesis, University of Oxford, 2017. http://ora.ox.ac.uk/objects/uuid:5558a55e-bb47-4b29-a681-1e58771abd1d.

Full text
Abstract:
Antibodies are soluble proteins produced by the adaptive immune system to bind and counteract invading pathogens. The binding properties of a typical human antibody are determined by the structure of its variable domain, composed of two chains – heavy and light and by the conformation of six loops located on the surface of the variable domain, known as Complementarity Determining Regions (CDRs). In the first chapter, we describe our analysis of the conformational space occupied by five out of six antibody CDRs (L1, L2, L3, H1 and H2) and the development of a novel, length-independent method for grouping these CDRs into structural clusters (canonical forms). We show that using our method we can increase coverage and precision of assigning CDR sequences into clusters. In the next chapter, we describe a method for ranking structural decoys of the CDR-H3 loop. We show that by computationally perturbing CDR-H3 decoys we can improve the performance of existing ranking methods. In the same chapter, we discuss the development of a method for high-throughput assignment of heavy-light chain orientation. The power of the method was demonstrated by assigning orientation to billions of potential Fv sequences. The third Chapter describes the analysis of a large dataset of CDR sequences with the aim of identifying sequence patterns responsible for the loops' structure. Using a neural network methodology, we found several groups of CDR sequences which might be indicative of previously-unseen conformations. In the final results Chapter, we describe how we used the structural knowledge developed throughout the rest of the thesis to create a novel pipeline for computational antibody design. We show that the binders developed using our methodology had similar features to available antibody therapeutics and low predicted propensity to cause an immunogenic response. These results demonstrate the potential for using computational methods for designing high affinity therapeutics with human properties.
APA, Harvard, Vancouver, ISO, and other styles
8

Kelly, Ryan L. (Ryan Lewis). "Determinants of antibody specificity." Thesis, Massachusetts Institute of Technology, 2017. http://hdl.handle.net/1721.1/112506.

Full text
Abstract:
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biological Engineering, 2017.
Cataloged from PDF version of thesis.
Includes bibliographical references (pages 134-146).
High throughput screening methods such as yeast surface display (YSD) are frequently able to isolate high affinity antibodies against clinical targets; however, the success of these candidates depends on selecting for both on-target binding and desirable biophysical characteristics. Development liabilities, including antibody aggregation and nonspecificity, can lead to problems during production and poor pharmacokinetics (PK). The exact structural and sequence determinants causing this poor developability are unknown, which leads to inexact methods to correct otherwise promising clinical candidates. In this thesis we outline the development of high throughput methods to interrogate developability of candidate antibodies on the surface of yeast and apply these methods to both determine the causes of nonspecificity and create new libraries with improved biophysical properties. We first analyzed methods for early stage assessment of monoclonal antibodies, finding a polyspecificity reagent (PSR) binding assay on the surface of yeast which can accurately predict antibody clearance rates in mice. While robust, this assay relies on production of a poorly defined mixture of protein components, and thus, we next looked at potential alternatives to a multicomponent PSR reagent. We found that chaperone proteins may work as well-defined, easily producible reagents with similar broad predictive power to predict downstream antibody behavior. Next, we applied these assays to assess core determinants of nonspecificity. We first analyzed a case study of two antibodies with identical target antigens but vastly different performance on preclinical assessments of biophysical characteristics. Through this matched case, we found differences in clearance rates can be driven wholly by variable-region mediated effects independent of neonatal Fc receptor (FcRn) binding. Focused on the antibody variable region, we next utilized our nonspecificity assay as a sorting tool to look at a naive repertoire library. We found significant nonspecificity in the VH6 class of antibodies, driven by a poorly behaved complementarity determining region (CDR) H2 sequence. Subsequently, we applied a similar sorting technique to two synthetic library designs to identify a set of motifs that can drive nonspecificity. These included motifs containing tryptophan, valine, glycine and arginine located in CDR H3. We then applied these discoveries to the design of a new, semi-synthetic single chain variable fragment (scFv) library and demonstrated its ability to isolate high affinity, highly specific candidate clones against a panel of antigens. Finally, we explored the use of an alternate yeast display system capable of easily switching between scFv-Fc display and secretion, which may aid in the rapid development and testing of candidate antibodies. Taken in whole, the work in this thesis aids the clinical development of antibodies. We have presented both methods to assess nonspecificity at an early stage in the development process as well as a set of motifs to be eliminated in future library designs. With these combined findings, we hope to increase the utilization of in vitro screening methods such as yeast display for the isolation of clinical candidate antibodies with favorable biophysical characteristics.
by Ryan L. Kelly.
Ph. D.
APA, Harvard, Vancouver, ISO, and other styles
9

Bidgood, Susanna Ruth. "Antibody mediated intracellular immunity." Thesis, University of Cambridge, 2013. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.648288.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ozeren, Muserref. "Catalysis by polyclonal antibody." Thesis, University of Bath, 1997. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.246006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Antibody"

1

Antibody therapy. Oxford: Bios Scientific, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lo, Benny K. C. Antibody Engineering. New Jersey: Humana Press, 2003. http://dx.doi.org/10.1385/1592596665.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Pezer, Marija, ed. Antibody Glycosylation. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-76912-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chames, Patrick, ed. Antibody Engineering. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-61779-974-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Whittaker, Kelly C., and Ruo-Pan Huang, eds. Antibody Arrays. New York, NY: Springer US, 2021. http://dx.doi.org/10.1007/978-1-0716-1064-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kontermann, Roland, and Stefan Dübel, eds. Antibody Engineering. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-642-01144-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kontermann, Roland, and Stefan Dübel, eds. Antibody Engineering. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-642-01147-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nevoltris, Damien, and Patrick Chames, eds. Antibody Engineering. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-8648-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kontermann, Roland, and Stefan Dübel, eds. Antibody Engineering. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-662-04605-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Imbach, Paul, ed. Antibody Therapy. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-68038-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Antibody"

1

Hasson, Brian F., Charlie Ma, Lu Wang, David E. Wazer, Jay E. Reiff, Jay E. Reiff, Brandon J. Fisher, et al. "Antibody." In Encyclopedia of Radiation Oncology, 19. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-540-85516-3_668.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Nahler, Gerhard. "antibody." In Dictionary of Pharmaceutical Medicine, 9. Vienna: Springer Vienna, 2009. http://dx.doi.org/10.1007/978-3-211-89836-9_72.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Peretó, Juli. "Antibody." In Encyclopedia of Astrobiology, 99. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-662-44185-5_343.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mehlhorn, Heinz. "Antibody." In Encyclopedia of Parasitology, 1–3. Berlin, Heidelberg: Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-642-27769-6_218-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Peretó, Juli. "Antibody." In Encyclopedia of Astrobiology, 47. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-11274-4_343.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Schaub, Günter, Hans Martin Seitz, and Ingrid Reiter-Owona. "Antibody." In Encyclopedia of Parasitology, 161–63. Berlin, Heidelberg: Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-662-43978-4_218.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gooch, Jan W. "Antibody." In Encyclopedic Dictionary of Polymers, 874. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-6247-8_13137.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Peretó, Juli. "Antibody." In Encyclopedia of Astrobiology, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-27833-4_343-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Peretó, Juli. "Antibody." In Encyclopedia of Astrobiology, 126. Berlin, Heidelberg: Springer Berlin Heidelberg, 2023. http://dx.doi.org/10.1007/978-3-662-65093-6_343.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Strebe, Nina, Frank Breitling, Dieter Moosmayer, Bodo Brocks, and Stefan Dübel. "Cloning of Variable Domains from Mouse Hybridoma by PCR." In Antibody Engineering, 3–14. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-642-01144-3_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antibody"

1

Haber, Edgar, Marchall T. Runge, Christoph Bode, Betsy Branscomb, and Janet Schnee. "ANTIBODY TARGETED FIBRINOLYSIS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643723.

Full text
Abstract:
Chemical conjugates of fibrin-specificantibodies and plasminogen activators. Urokinase or tPA were linked covalently toamonoclonal antibody specific for the amino terminus of the beta chain of human fibrin (59D8) by means of the unidirectionalcross-linking reagent SPDP. The fibrinolytic potency of the conjugates at equal amidolytic activities was compared to the native plasminogen activators in an assay measuring lysis of 1251-fibrin monomer covalently linked to Sepharose CL-4B. Urokinase was least potent, tPA exhibited a 10fold increase in fibrinolysis whereas both the urokinase and tPA antibody conjugates and a urokinase-Fab conjugate were 250fold more potent than urokinase and 25 fold more potent than tPA. Enhanced fibrinolysis was fully inhibited by b peptide indicating its dependence on antigen binding. In a plasma assay conjugates of tPA orUK to antibody produced a 3.2- to 4.5-fold enhancement in clot lysis in human plasma over that of the respective unconjugated plasminogen activator. However, the UK-59D8 conjugate was only as potent as tPAalone. Antibody-conjugated tPA or UK consumed less fibrinogen, alpha 2-antiplasminand plasminogen than did the unconjugatedactivators, at equipotent thrombolytic concentrations. In a quantitative rabbit thrombolysis model, the activity of the purified conjugate was compared with that oftPA alone and that of a conjugate betweentPA and a digoxin-specific monoclonal antibody. After correction for spontaneous lysis, tPA-59D8 was shown to be 2.8 to,9.6times more potent than tPA alone. Unconjugated tPA and tPA-digoxin were equipotent.At equivalent thrombolytic concentrations, tPA-59D8 degraded less fibrinogen and consumed less alpha 2-antiplasmin than did tPA alone. These results suggest that tPA can be efficiently directed to the site of a thrombus by conjugation to an antifibrin monoclonal antibody, resulting in both more potent and more selective thrombolysis.A recombinant fusion protein comprising a fibrin-specific antibody site and theB chain of tPA. The rearranged 59D8 heavychain gene was cloned and combined in theexpression vector pSV2gpt withsequence coding for a portion of the Gamma 2b constant region and the catalytic beta chain of t-PA. This construct was transfected into heavy chain loss variant cells derived from the 59D8 hybridoma. Recombinant protein was purified by affinitychromatography and analyzed with Western blots. These revealed a 65-kD heavy chain-t-PA fusion protein that is secreted in association with the 59D8 light chain in the form of a 170-kD disulfide linked dimer. A chromogenic substrate assay showed the fusion protein to have 70 percent of the peptidolytic activity of native t-PA and to activate plasminogen as efficiently as t-PA. In a competitive binding assay, reconstituted antibody was shown to have a binding profile similar to that of native 59D8. Thus by recombinant techniques we have produced a novel hybrid protein capable of high affinity fibrin binding andplasminogen activation.Chemical conjugates between a fibrin-specific and a tPA-specific antibody. A heteroantibody duplex (duplex) with specificities for both tPA and fibrin was synthesized by conjugating iminothiolane-modified anti-tPA monoclonal antibody (TCL8) toantifibrin antibody 59D8. Addition of both duplex and tPA to a plasma clot assay gave more lysis (200 units produced 23.1 lysis; 400 units, 29.5 lysis) than did tPAalone (200 units, 1.8% lysis; 400 units,19% lysis). Despite increased potency associated with duplex addition, fibrinogen and alpha-2-antiplasmin levels at equal tPA concentrations did not differ. Thus, itis possible to concentrate tPA (added separately) to the site of a thrombus in plasma using a heteroantibody duplex with specificities for both tPA and fibrin.Biosynthetically produced heteroduplexantibodies that are both fibin and tPA-specific. The bispecific antibodies were prepared in two ways. First, polyethylene glycol-mediated fusions were performed with two different hybridoma cell lines: anti-fribrin b chain producer, 59D8 and anti-tPA producer, TCL8. TCL8 cells were selected for HPRT-minus variants and then fused with TK-deficient 59D8 cells. One cell line, F36.23, possessed both anti-human fibrin and anti-human t-PA immunoreactivities. A second method yielded another bispecific antibody, F32.1. This cell line was selected after fusing TCL8 (HPRT-minus) cells with spleen cells from a mouseimmunized with a fibrin-like peptide corresponding to the amino terminus of fibrinalpha-chains. Affinity-purified F32.1 andF36.23 retained anti-fibrin and anti-t-PAactivity and enhanced fibrinolytic potency of tPA by a factor of 10.
APA, Harvard, Vancouver, ISO, and other styles
2

Gao, Kaiyuan, Lijun Wu, Jinhua Zhu, Tianbo Peng, Yingce Xia, Liang He, Shufang Xie, et al. "Pre-training Antibody Language Models for Antigen-Specific Computational Antibody Design." In KDD '23: The 29th ACM SIGKDD Conference on Knowledge Discovery and Data Mining. New York, NY, USA: ACM, 2023. http://dx.doi.org/10.1145/3580305.3599468.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Omer Mahgoub, Ilham. "Design, Expression And Characterization Of A Single Chain Fragment Variable Anti-mcf-7 Antibody; A Humanized Antibody Derived From Monoclonal Antibody." In Qatar Foundation Annual Research Conference Proceedings. Hamad bin Khalifa University Press (HBKU Press), 2014. http://dx.doi.org/10.5339/qfarc.2014.hbpp0705.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Diamond, B., Y. Arinuma, F. Yuichiro, C. Kowal, J. Nestor, P. Huerta, and B. Volpe. "13 Antibody-mediated neuropsychiatric lupus." In LUPUS 2017 & ACA 2017, (12th International Congress on SLE &, 7th Asian Congress on Autoimmunity). Lupus Foundation of America, 2017. http://dx.doi.org/10.1136/lupus-2017-000215.13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Menking, Darrell E., Jonathon M. Heitz, Nabil A. Anis, and Roy G. Thompson. "Antibody-based bacterial toxin detection." In Optical Tools for Manufacturing and Advanced Automation, edited by Robert A. Lieberman. SPIE, 1994. http://dx.doi.org/10.1117/12.170668.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Rivolo, P., G. Digregorio, F. Frascella, P. Mandracci, M. Ballarini, F. Giorgis, E. Descrovi, L. Dominici, and F. Michelotti. "Realtime antibody-antibody detection by means of Bloch surface waves on silicon-based multilayers." In 2011 International Workshop on Biophotonics. IEEE, 2011. http://dx.doi.org/10.1109/iwbp.2011.5954810.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hoshino, Akiyoshi, Tomokazu Nagao, Kenji Yamamoto, and Kazuo Suzuki. "Trace of antibody to myeloperoxidase with nanocrystal quantum dot-labeled antibody recognizing activating neutrophils." In Biomedical Optics 2006, edited by Marek Osinski, Kenji Yamamoto, and Thomas M. Jovin. SPIE, 2006. http://dx.doi.org/10.1117/12.645475.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kano, Koji, Hiromi Yatsuda, and Jun Kondoh. "Evaluation of detectable depth on SH-SAW biosensor using antibody, antigen, and secondary antibody complexes." In 2019 IEEE International Ultrasonics Symposium (IUS). IEEE, 2019. http://dx.doi.org/10.1109/ultsym.2019.8925760.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Chabot, J. R., D. E. Dettling, P. J. Jasper, and B. C. Gomes. "Comprehensive mechanism-based antibody pharmacokinetic modeling." In 2011 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 2011. http://dx.doi.org/10.1109/iembs.2011.6091072.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

OU, CHUNG MING. "Associative Memory Inspired by Antibody Dynamics." In Fifth International Conference on Advances in Computing, Communication and Information Technology - CCIT 2017. Institute of Research Engineers and Doctors, 2017. http://dx.doi.org/10.15224/978-1-63248-131-3-26.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Antibody"

1

ZALUTSKY, MICHAEL R. Recombinant anti-tenascin antibody constructs. Office of Scientific and Technical Information (OSTI), August 2006. http://dx.doi.org/10.2172/890551.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

German, Dwight. Serum Antibody Biomarkers for ASD. Fort Belvoir, VA: Defense Technical Information Center, October 2014. http://dx.doi.org/10.21236/ada612324.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zhang, Yan. Antibody Microchips to Study Metastasis. Fort Belvoir, VA: Defense Technical Information Center, July 2003. http://dx.doi.org/10.21236/ada418683.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kuhn, Raymond E. Antigen-Antibody Analysis in Leishmaniasis. Fort Belvoir, VA: Defense Technical Information Center, April 1990. http://dx.doi.org/10.21236/ada266253.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Weiner, Louis M. Antibody - Pretargeted Cytokine Therapy of Cancer. Fort Belvoir, VA: Defense Technical Information Center, May 2001. http://dx.doi.org/10.21236/ada395111.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Weiner, Louis M. Antibody - Pretargeted Cytokine Therapy of Cancer. Fort Belvoir, VA: Defense Technical Information Center, May 2002. http://dx.doi.org/10.21236/ada407653.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Weiner, Louis M. Antibody - Pretargeted Cytokine Therapy of Cancer. Fort Belvoir, VA: Defense Technical Information Center, June 2003. http://dx.doi.org/10.21236/ada418149.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kent, Michael. Computational Modeling To Adapt Neutralizing Antibody. Office of Scientific and Technical Information (OSTI), October 2020. http://dx.doi.org/10.2172/1673826.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Weiner, Louis. Antibody - Pretargeted Cytokine Therapy of Cancer. Fort Belvoir, VA: Defense Technical Information Center, May 2000. http://dx.doi.org/10.21236/ada382515.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Loomis, Larry, and James E. Morris. Antibody-Based Diagnostics: Fast Track Production. Office of Scientific and Technical Information (OSTI), September 2011. http://dx.doi.org/10.2172/1024545.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Antibody' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography